Carcinosarcoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Podcasts
• Clinical Trials

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Conditions:   Ovarian Carcinosarcoma;   Uterine Carcinosarcoma Interventions:   Drug: Eribulin Mesylate;   Drug: Pembrolizumab Sponsors:   Australia New Zealand Gynaecological Oncology Group;   Eisai Inc.;   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2022 Category: Research Source Type: clinical trials